SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy’s Laboratories trades higher on launching Vozet Tablets in Indian market

19 Jul 2017 Evaluate

Dr. Reddys Laboratories is currently trading at Rs. 2748.50, up by 32.85 points or 1.21% from its previous closing of Rs. 2715.65 on the BSE.

The scrip opened at Rs. 2730.00 and has touched a high and low of Rs. 2758.00 and Rs. 2723.00 respectively. So far 11139 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3689.00 on 20-Jul-2016 and a 52 week low of Rs. 2382.05 on 29-May-2017.

Last one week high and low of the scrip stood at Rs. 2758.00 and Rs. 2685.00 respectively. The current market cap of the company is Rs. 45650.44 crore.

The promoters holding in the company stood at 26.79 %, while Institutions and Non-Institutions held 42.95% and 13.87% respectively.

Dr. Reddy’s Laboratories has launched Vozet Tablets in Indian market. The drug is indicated for the treatment of allergic Rhinitis and chronic Urticaria. Vozet Tablets contain Levocetirizine 5 mg, and are available in a strip size of 10 tablets.

The anti-histamine market in India had sales of Rs 1,038 crore MAT for the most recent twelve months ended in March 2017, according to IMS data. The pharma major will further strengthen its anti-allergy portfolio with the addition of Vozet.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.


Dr. Reddys Lab Share Price

1293.00 -0.25 (-0.02%)
11-May-2026 09:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1839.85
Dr. Reddys Lab 1293.00
Cipla 1340.75
Zydus Lifesciences 940.00
Lupin 2344.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×